Results 31 to 40 of about 18,898 (135)

Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment

Current Issues in Molecular Biology, 2023
Diabetes mellitus is a chronic multisystem disease with a high global prevalence. The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is known to lower glucose levels and reduce weight.
Mohamed Rafiullah, Hicham Benabdelkamel, Afshan Masood, Aishah A. Ekhzaimy, Mohthash Musambil, Salini Scaria Joy, Assim A. Alfadda   +6 more
doaj   +1 more source

Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons – Implications for energy balance and glucose control

Molecular Metabolism, 2019
Objective: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, stimulates insulin secretion and efficiently suppresses food intake to reduce body weight.
Zhenyan He, Yong Gao, Linh Lieu, Sadia Afrin, Jianhong Cao, Natalie J. Michael, Yanbin Dong, Jia Sun, Hongbo Guo, Kevin W. Williams   +9 more
doaj   +1 more source

Liraglutide Ameliorates β-Amyloid Deposits and Secondary Damage in the Ipsilateral Thalamus and Sensory Deficits After Focal Cerebral Infarction in Rats

Frontiers in Neuroscience, 2018
Focal cerebral infarction causes β-amyloid (Aβ) deposition and secondary neuronal degeneration in the ipsilateral thalamus. Thalamus is the subcortical center of sensory, the damage of thalamus could cause sensory deficits.
Hui-Li Zhu, Hui-Li Zhu, Zhang-Pei Liu, Zhang-Pei Liu, Wan-Yong Yang, Wan-Yong Yang, Da-Wei Dong, Da-Wei Dong, Ying Zhao, Ying Zhao, Bing Yang, Bing Yang, Li-An Huang, Li-An Huang, Yu-Sheng Zhang, Yu-Sheng Zhang, An-Ding Xu, An-Ding Xu   +17 more
doaj   +1 more source

Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials

Clinical and Experimental Hypertension, 2020
The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients.
Di Zhao, Hui Liu, Pingshuan Dong
doaj   +1 more source

Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitus

Saudi Pharmaceutical Journal
Liraglutide, a type2 diabetes mellitus (T2DM)-related treatment, improves glycemic control and reduces the risks of adverse cardiovascular events in T2DM patients.
Hicham Benabdelkamel, Rajaa Sebaa, Reem H. AlMalki, Afshan Masood, Assim A. Alfadda, Anas M. Abdel Rahman   +5 more
doaj   +1 more source

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

Obesity Facts, 2017
Objective: To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to Methods: A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and ...
Carel le Roux, Vanita Aroda, Joanna Hemmingsson, Ana Paula Cancino, Rune Christensen, Xavier Pi-Sunyer   +5 more
doaj   +1 more source

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats [PDF]

PeerJ, 2019
Background and Aims Many studies have revealed that glucagon-like peptide-1 has vasoprotective effects. In this study, we investigated whether liraglutide suppressed endothelial dysfunction and explored the mechanism involved.
Qian Zhang, Xinhua Xiao, Jia Zheng, Ming Li   +3 more
doaj   +2 more sources

Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway

International Journal of Endocrinology, 2020
Liraglutide is a glucagon-like peptide-1 analogue widely used in the treatment of type 2 diabetes mellitus. However, the effects of liraglutide on osteoblast proliferation and differentiation in MC3T3-E1 cells have not been fully elucidated.
Yue Sun, Yuzhen Liang, Zhengming Li, Ning Xia   +3 more
doaj   +1 more source

Association Between Exercise and Treatment with Liraglutide in Obese Rats by Cafeteria Diet [PDF]

Brazilian Archives of Biology and Technology, 2019
The objective of this study was to evaluate the effect of liraglutide, an analog of glucagon-like peptide-1 (GLP-1) in association with physical exercise, on the metabolic and biochemical parameters of rats induced to obesity with a cafeteria diet.
Daiane Didek, Maiara Mikuska Cordeiro, João Lucas de Paula Xavier, Paulo Roberto Ribeiro, Thiago Rentz, Gilson Cesar Nobre Franco, Carla Cristine Kanunfre, Henriette Rosa de Oliveira Emilio, Dionízia Xavier Scomparin   +8 more
doaj   +1 more source

Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Saudi Pharmaceutical Journal, 2020
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use.
Abdullah F. AlAsmari, Nemat Ali, Fawaz AlAsmari, Wael A. AlAnazi, Musaad A. AlShammari, Naif O. Al-Harbi, Ali Alhoshani, Homood M. As Sobeai, Mohammed AlSwayyed, Mohammed M. AlAnazi, Nader S. AlGhamdi   +10 more
doaj   +1 more source